Though Relugolix was available in developed countries since the last four years, patients in India did not have access to it. With this launch, Zydus brings both access to a critical therapy and also makes it affordable at a cost of Rs. 6995 per month which is 50% less than the currently available injectable options.

The drug will be manufactured at the group's manufacturing premises. This marks a big leap forward in the management of prostate cancer as patients and doctors will have a new option which can offer convenience, safety and rapid action.